Winkelmeier, Laurens http://orcid.org/0000-0002-9103-5983
Maros, Máté
Flottmann, Fabian
Heitkamp, Christian
Schön, Gerhard
Thomalla, Götz
Fiehler, Jens
Hanning, Uta
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 8 January 2024
Accepted: 14 April 2024
First Online: 30 April 2024
Conflict of interest
: L. Winkelmeier, C. Heitkamp, G. Schön declare that they have no competing interests. M. Maros, F. Flottmann: Personal fees from Eppdata. G. Thomalla: Personal fees from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Daiichi Sankyo, Portola, and Stryker. J. Fiehler: Personal fees from Acandis, Cerenovus, Medtronic, MicroVention, Medtronic, Penumbra, Phenox, Stryker, Tonbride, and Roche; stocks or stock options from Tegus Medical, Eppdata, and Vastrax. U. Hanning: Personal fees from Eppdata and Stryker.